![]() |
|
|
Vol. 30, Issue 7, 853-858, July 2002
Université Claude Bernard Lyon 1, Département de
Pharmacie Clinique de Pharmacocinétique et d'Evaluation du
Médicament; and Hôpital Neuro-Cardiologique, Laboratoire de
Dosage des Médicaments, Lyon Cedex, France
Ketamine is a widely used drug for its anesthetic and analgesic
properties; it is also considered as a drug of abuse, as many cases of
ketamine illegal consumption were reported. Ketamine is
N-demethylated by liver microsomal cytochrome P450 into
norketamine. The identification of the enzymes responsible for ketamine
metabolism is of great importance in clinical practice. In the present
study, we investigated the metabolism of ketamine in human liver
microsomes at clinically relevant concentrations. Liver to plasma
concentration ratio of ketamine was taken into consideration. Pooled
human liver microsomes and human lymphoblast-expressed P450
isoforms were used. N-demethylation of ketamine was
correlated with nifedipine oxidase activity (CYP3A4-specific marker
reaction), and it was also correlated with S-mephenytoin
N-demethylase activity (CYP2B6-specific marker
reaction). Orphenadrine, a specific inhibitor to CYP2B6, and
ketoconazole, a specific inhibitor to CYP3A4, inhibited the N-demethylation of ketamine in human liver microsomes.
In human lymphoblast-expressed P450, the activities of CYP2B6 were
higher than those of CYP3A4 and CYP2C9 at three concentrations of
ketamine, 0.005, 0.05, and 0.5 mM. When these results were extrapolated using the average relative content of these P450 isoforms in human liver, CYP3A4 was the major enzyme involved in ketamine
N-demethylation. The present study demonstrates that
CYP3A4 is the principal enzyme responsible for ketamine
N-demethylation in human liver microsomes and that
CYP2B6 and CYP2C9 have a minor contribution to ketamine N-demethylation at therapeutic concentrations of the drug.
This article has been cited by other articles:
![]() |
M. P. Larenza, M. F. Landoni, O. L. Levionnois, M. Knobloch, P. W. Kronen, R. Theurillat, U. Schatzmann, and W. Thormann Stereoselective pharmacokinetics of ketamine and norketamine after racemic ketamine or S-ketamine administration during isoflurane anaesthesia in Shetland ponies Br. J. Anaesth., February 1, 2007; 98(2): 204 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Walsky, A. V. Astuccio, and R. S. Obach Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6. J. Clin. Pharmacol., December 1, 2006; 46(12): 1426 - 1438. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. F. Rehmel, J. A. Eckstein, N. A. Farid, J. B. Heim, S. C. Kasper, A. Kurihara, S. A. Wrighton, and B. J. Ring INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 Drug Metab. Dispos., April 1, 2006; 34(4): 600 - 607. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Williams, D. E. Mager, H. Parenteau, G. Gudi, T. S. Tracy, M. Mulheran, and I. W. Wainer EFFECTS OF PROTEIN CALORIE MALNUTRITION ON THE PHARMACOKINETICS OF KETAMINE IN RATS Drug Metab. Dispos., August 1, 2004; 32(8): 786 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hijazi, C. Bodonian, M. Bolon, F. Salord, and R. Boulieu Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury Br. J. Anaesth., February 1, 2003; 90(2): 155 - 160. [Abstract] [Full Text] [PDF] |
||||